
Auteur M. PAZITNY
|
Documents disponibles écrits par cet auteur (3)

Nouveauté
V. BELACKOVA ; M. PAZITNY ; E. DRAPALOVA ; M. MARTINEZ ; D. VAN DER GOUWE ; E. BEGLEY ; M. KIDAWA ; A. TOMKOVA ; D. KMETONYNOVA | 2018
Dans Drugs: Education, Prevention and Policy (Vol.25, n°2, April 2018) Article : PériodiqueAims: The indicator of availability has been used in the risk assessment (RA) of new psychoactive substances (NPS). This paper aims to examine the pre- and post-control availability of 25I-NBOMe, AH-7921, MDPV and MXE, which were assessed by the[...]
B. GUARITA ; V. BELACKOVA ; D. VAN DER GOUWE ; M. BLANKERS ; M. PAZITNY ; P. GRIFFITHS | 2021
Dans International Journal of Drug Policy (Vol.94, August 2021) Article : PériodiqueDevelopments in information technology have impacted on all areas of modern life and in particular facilitated the growth of globalisation in commerce and communication. Within the drugs area this means that both drugs discourse and drug markets[...]Nouveauté
T. M. BRUNT ; A. M. ATKINSON ; T. NÉFAU ; M. MARTINEZ ; E. LAHAIE ; A. MALZCEWSKI ; M. PAZITNY ; V. BELACKOVA ; S. D. BRANDT | 2017
Dans International Journal of Drug Policy (Vol.44, June 2017) Article : PériodiqueBackground: New psychoactive substances (NPS) are on offer worldwide online, in order to shed light on the purity and price of these substances in the European Union, a research collaboration was set up involving France, United Kingdom (UK), the[...]